2 weeks Ago By Defense World Staff
Legal & General Group Plc cut its holdings in Amgen Inc. ( NASDAQ:AMGN – Free Report ) by 2.7% during the 2nd quarter, according to its most recent disclosure with the SEC.
The institutional investor owned 4,839,038 shares of the medical research company’s stock after selling 135,328 shares during the period. Legal & General Group Plc owned approximately 0.90% of Amgen worth $1,511,957,000 as of its most recent filing with the SEC.
A number of other hedge funds have also bought and sold shares of the business. Strategic Financial Concepts LLC bought a new position in shares of Amgen during the second quarter worth approximately $26,000. Horizon Financial Services LLC bought a new position in Amgen during the 1st quarter worth $28,000.
United Community Bank bought a new position in Amgen during the 4th quarter worth $29,000. nVerses Capital LLC acquired a new position in Amgen in the 2nd quarter valued at $31,000. Finally, Bbjs Financial Advisors LLC bought a new stake in shares of Amgen during the 2nd quarter valued at $33,000.
76.50% of the stock is owned by institutional investors. Amgen Stock Performance Shares of Amgen stock opened at $319.
10 on Friday. The stock has a market cap of $171.18 billion, a price-to-earnings ratio of 45.
59, a P/E/G ratio of 2.98 and a beta of 0.61.
Amgen Inc. has a twelve month low of $249.70 and a twelve month high of $346.
85. The company’s fifty day moving average is $328.94 and its 200 day moving average is $307.
00. The company has a quick ratio of 0.89, a current ratio of 1.
26 and a debt-to-equity ratio of 9.64. Amgen Announces Dividend The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th.
Shareholders of record on Friday, August 16th were issued a dividend of $2.25 per share. The ex-dividend date was Friday, August 16th.
This represents a $9.00 annualized dividend and a yield of 2.82%.
Amgen’s payout ratio is 128.57%. Analyst Ratings Changes A number of research analysts recently commented on AMGN shares.
Dbs Bank raised Amgen to a “strong-buy” rating in a research note on Monday, September 16th. TD Cowen boosted their target price on shares of Amgen from $360.00 to $381.
00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $305.00 price target (down previously from $310.
00) on shares of Amgen in a report on Wednesday, August 7th. Jefferies Financial Group reissued a “buy” rating and issued a $380.00 price objective (up from $375.
00) on shares of Amgen in a research note on Wednesday, August 7th. Finally, Robert W. Baird restated an “underperform” rating and set a $215.
00 target price on shares of Amgen in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and an average target price of $321.
37. Read Our Latest Stock Report on AMGN Amgen Company Profile ( Free Report ) Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also Five stocks we like better than Amgen What is the Hang Seng index? REITs on the Rise After Rate Cuts: Where to Invest Now Why Invest in 5G? How to Invest in 5G Stocks Is Viking Therapeutics Ready For Another Surge? How to Invest in Tech Stocks and Top Tech Stocks to Consider AI Boom and Rate Cuts Boost Utility Stocks: Best Growth Picks Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. ( NASDAQ:AMGN – Free Report ).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter ..
